Cellectis (CLLS)
(Delayed Data from NSDQ)
$2.35 USD
-0.03 (-1.06%)
Updated Aug 28, 2024 02:49 PM ET
3-Hold of 5 3
B Value B Growth D Momentum B VGM
Industry / Sector Report
Industry : Medical - Biomedical and Genetics
Zacks Industry Rank
Top 33% (83 out of 251)Zacks Sector Rank
Top 31% (5 out of 16)Recommendations and Estimates
Company | Industry | SP500 | |
---|---|---|---|
Average Recommendation (1=Buy, 5=Sell) | 1.33 | 1.36 | 9.99 |
Current Quarter Estimate | -0.20 | 2.97 | 61.00 |
Year Ago Quarter Estimate | -0.31 | -4.89 | 54.84 |
Next Quarter Estimate | -0.09 | 4.11 | 63.00 |
Next Year Estimate | -0.51 | 25.30 | 275.00 |
Growth Rates
Company | Industry | SP500 | |
---|---|---|---|
This Year | 73.66 | 18.20 | 15.67 |
Next Year | 5.56 | 9.30 | 11.34 |
Last 5 Years | -367.50 | 0.90 | 8.10 |
Next 5 Years | NA | 21.60 | NA |
Financials
Company | Industry | |
---|---|---|
Price/Earnings (TTM) | NA | -7.33 |
Price/Book (MRQ) | 0.89 | 2.09 |
Price/Cash Flow (MRFY) | NA | 17.39 |
Dividend Yield | 0.00% | 0.00% |
Net Profit Margin (TTM) | -401.83% | -147.72% |
Return on Equity (TTM) | -78.91% | -60.38% |
Debt to Equity (MRQ) | 0.39 | 0.00 |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.